Cooper Companies Posts 15% EPS Gain

Cooper Companies (NASDAQ:COO) reported Q3 FY2025 results with organic revenue growth slowing sharply to 2%, missing expectations due to inventory destocking and soft market conditions, particularly in Asia Pacific. Despite top-line weakness, non-GAAP EPS climbed 15% to $1.10, surpassing forecasts, driven by robust cost controls and operational efficiencies. Management subsequently raised full-year non-GAAP EPS guidance while trimming revenue forecasts, signaling a strategic focus on profitability amid decelerating sales and raising questions about the sustainability of earnings growth without a broader market recovery.

Analysis

Cooper Companies reported a mixed third quarter for fiscal 2025, characterized by a sharp divergence between decelerating top-line growth and robust bottom-line execution. Organic revenue growth slowed significantly to just 2%, a steep drop from 7% in the prior quarter and below market expectations, driven by inventory destocking and market softness, particularly in the Asia Pacific region where CooperVision sales declined 5% organically. Despite this revenue weakness, the company demonstrated strong operational discipline, delivering a 15% year-over-year increase in non-GAAP EPS to $1.10, which surpassed forecasts. This profitability was fueled by effective cost controls, leading to a 1.0 percentage point expansion in non-GAAP gross margin to 67%. Management's revised guidance encapsulates this dynamic: the full-year revenue forecast was lowered to a 4-4.5% organic growth range, down from 5-6%, while the full-year non-GAAP EPS outlook was raised to $4.08–$4.12. This strategic pivot towards prioritizing margins over volume growth raises questions about the sustainability of earnings momentum if underlying sales fail to reaccelerate.

Key Decisions for Investors

• Investors should weigh the company's demonstrated ability to expand margins and beat earnings estimates against the significant deceleration in organic revenue and the lowered full-year sales guidance.
• Monitor leading indicators for a top-line recovery, specifically the conversion rate of MiSight lens trials into sustainable sales and any stabilization in the challenged Asia Pacific market.
• Consider that while the company is exhibiting defensive qualities through strong cost control and share repurchases, the slowing growth profile may challenge its valuation as a growth-focused medical device company.